Free press releases distribution network?

Agency / Source: Becton, Dickinson and Company

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



BD Diagnostics Advances Commitment to a Fully Integrated Microbiology Solution with New Agreement - BD Diagnostics, a segment of BD (Becton, Dickinson and Company), announced today an international distributor agreement with Bruker Daltonics Inc. to sell and provide front-line technical support for the co-labeled BD™ Bruker MALDI Biotyper™ System - BD.c
BD Diagnostics Advances Commitment to a Fully Integrated Microbiology Solution with New Agreement

 

PRZOOM - /newswire/ - Sparks, MD, United States, 2013/04/27 - BD Diagnostics, a segment of BD (Becton, Dickinson and Company), announced today an international distributor agreement with Bruker Daltonics Inc. to sell and provide front-line technical support for the co-labeled BD™ Bruker MALDI Biotyper™ System - BD.c. NYSE: BDX

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Microbial identification and antimicrobial susceptibility testing is the end-point of the majority of work a microbiology lab performs on a daily basis and is very time consuming. The BD™ Bruker MALDI Biotyper™ System combined with automated antimicrobial susceptibility testing on the BD Phoenix™ Microbiology System and the BD EpiCenter™ Microbiology Data Management System, will facilitate a fully integrated, optimized approach for laboratory workflow.

“BD believes mass spectrometry technologies are the future of microbial identification,” said Jamie Condie, Vice President and General Manager, BD Diagnostics Diagnostic Systems, Infectious Disease. “Combining Bruker’s expertise in this area with our advanced lab automation experience, the BD™ Bruker MALDI Biotyper™ System will enhance our customers’ clinical decision making and laboratory workflow.”

Antimicrobial susceptibility testing is conducted via traditional automated systems such as the BD Phoenix System. The combination of these two proven technologies, the BD Phoenix System and the Bruker MALDI Biotyper, and data management through the BD EpiCenter System, will provide laboratorians with a new approach to identification and susceptibility testing, which is expected to reduce the turnaround time for critical diagnostic results, while also improving laboratory efficiency and costs. Identification of pathogens will occur in minutes versus hours directly impacting patient management.

The Bruker MALDI Biotyper is currently not available in the United States for in vitro diagnostic use.

This announcement is an update to the joint collaboration, co-marketing, and co-selling agreement with Bruker Daltonics Inc. in 2010.

About the BD Bruker MALDI Biotyper System
The dedicated MALDI Biotyper solution enables molecular identification, and taxonomical classification or dereplication of microorganisms like bacteria, yeasts and fungi. Classification and identification of microorganisms is achieved reliably and quickly using proteomic fingerprinting by high-throughput MALDI-TOF mass spectrometry. Applications include clinical routine microbial identification, environmental and pharmaceutical analysis, taxonomical research, food and consumer product safety and quality control, as well as marine microbiology. The robust MALDI Biotyper method requires minimal sample preparation and offers low consumables cost. The MALDI Biotyper is available in a research-use-only version, or in an IVD-CE version according to EU directive EC/98/79 in various European countries. In the United States of America the MALDI Biotyper is available for research use only, and not for use in diagnostic procedures.

About BD
BD (bd.com) is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs nearly 30,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Becton, Dickinson and Company

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


BD Diagnostics Advances Commitment to a Fully Integrated Microbiology Solution with New Agreement

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
BD |
Contact: Jamie Yacco - BD.com 
201-847-4796 Jamie_Yacco[.]bd.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Becton, Dickinson and Company securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Becton, Dickinson and Company / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors
OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR
Bioinformatics Market Size to Expand at 20.4% CAGR through 2020 Reports Persistence Market Research
Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  RightITnow Ltd

Visit  BizJobs.com

Visit  La Bella Bakery Artisan Bakery Arizona







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today